Top

Published in:

09-04-2019 | Research Article

Plasma total antioxidant status and cognitive impairments in first-episode drug-naïve patients with schizophrenia

Authors: Ting Xie, Qiongwei Li, Xingguang Luo, Li Tian, Zhiren Wang, Shuping Tan, Song Chen, Guigang Yang, Huimei An, Fude Yang, Yunlong Tan

Published in: Cognitive Neurodynamics | Issue 4/2019

Activate our intelligent search to find suitable subject content or patents.

search-config

AI-assisted search

Off

Abstract

Accumulating evidence suggest that excessive reactive oxygen species-induced oxidative damage may underlie neurodegeneration and cognitive impairment in several disorders including schizophrenia. In this study we examined the association of oxidative stress with cognitive deficits in first-episode drug-naïve (FEDN) patients with schizophrenia. We recruited 54 FEDN patients and 50 age- and sex-matched healthy controls and examined the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus cognitive Battery (MCCB) and plasma total antioxidant status (TAS). Psychopathological symptoms were assessed using the Positive and Negative Syndrome Scale. The results showed that plasma TAS levels were significantly lower in the patients than those in the healthy subjects (94.7 ± 25.0 U/ml vs 156.6 ± 46.7 U/ml, p < 0.0001). The patients scored lower than healthy controls on the MCCB total score, speed of processing, attention/vigilance and managing emotion test index and STROOP test. For the patients, TAS was associated with some domains of cognitive deficits in schizophrenia, such as speed of processing, attention/vigilance and emotion managing. Our results suggested that oxidative stress may be involved in the pathophysiology of schizophrenia at the early of stage and its cognitive impairment.

previous article Flanker paradigm contains conflict and distraction factors with distinct neural mechanisms: an ERP analysis in a 2-1 mapping task

next article Consensus of uncertain multi-agent systems with input delay and disturbances

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 340 Zeitschriften

aus folgenden Fachgebieten:

Bauwesen + Immobilien
Business IT + Informatik
Finance + Banking
Management + Führung
Marketing + Vertrieb
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Akiibinu MO, Ogundahunsi OA, Ogunyemi EO (2012) Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics. BMC Res Notes 5:169PubMedPubMedCentralCrossRef

Alvarez JA, Emory E (2006) Executive function and the frontal lobes: a meta-analytic review. Neuropsychol Rev 16(1):17–42PubMedCrossRef

An H, Du X, Huang X et al (2018) Obesity, altered oxidative stress, and clinical correlates in chronic schizophrenia patients. Transl Psychiatry 8(1):258PubMedPubMedCentralCrossRef

Barch DM, Carter CS, Arnsten A et al (2009) Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull 35(1):109–114PubMedCrossRef

Barder HE, Sundet K, Rund BR et al (2013) Neurocognitive development in first episode psychosis 5 years follow-up: associations between illness severity and cognitive course. Schizophr Res 149(1–3):63–69PubMedCrossRef

Benzie IFF, Strain JJ (1996) The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem 239(1):70–76PubMedCrossRef

Bitanihirwe BK, Woo TU (2011) Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 35(3):878–893PubMedPubMedCentralCrossRef

Boskovic M, Vovk T, Plesnicar BK, Grabnar I (2011) Oxidative Stress in Schizophrenia. Curr Neuropharmacol 9(2):301–312PubMedPubMedCentralCrossRef

Dalby RB, Frandsen J, Chakravarty MM et al (2012) Correlations between Stroop task performance and white matter lesion measures in late-onset major depression. Psychiatry Res 202(2):142–149PubMedCrossRef

Davies KJ (2000) An overview of oxidative stress. IUBMB Life 50(4–5):241–244PubMedCrossRef

Erlenmeyer-Kimling L (2000) Neurobehavioral deficits in offspring of schizophrenic parents: liability indicators and predictors of illness. Am J Med Genet 97(1):65–71PubMedCrossRef

Flatow J, Buckley P, Miller BJ (2013) Meta-analysis of oxidative stress in schizophrenia. Biol Psychiat 74(6):400–409PubMedCrossRef

Gahtan E, Auerbach JM, Groner Y et al (1998) Reversible impairment of long-term potentiation in transgenic Cu/Zn–SOD mice. Eur J Neurosci 10(2):538–544PubMedCrossRef

George A, Ng CP, O’Callaghan M et al (2014) In vitro and ex vivo cellular antioxidant protection and cognitive enhancing effects of an extract of Polygonum minus Huds (Lineminus) demonstrated in a Barnes Maze animal model for memory and learning. BMC Complement Altern Med 14:161PubMedPubMedCentralCrossRef

Green MF, Nuechterlein KH (2004) The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res 72(1):1–3PubMedCrossRef

Green MF, Horan WP, Lee J (2015) Social cognition in schizophrenia. Nat Rev Neurosci 16(10):620–631PubMedCrossRef

Gunes M, Camkurt MA, Bulut M et al (2016) Evaluation of paraoxonase, arylesterase and malondialdehyde levels in schizophrenia patients taking typical, atypical and combined antipsychotic treatment. Clin Psychopharmacol Neurosci 14(4):345–350PubMedPubMedCentralCrossRef

Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J Neurochem 97(6):1634–1658PubMedCrossRef

Harvey PD (2014) What is the evidence for changes in cognition and functioning over the lifespan in patients with schizophrenia? J Clin Psychiatry 75(Suppl 2):34–38PubMedCrossRef

Hu HL, Wang T, Zhang ZX et al (2006) The effect of mitochondrial membrane potential on changes of reactive oxygen species and on proliferation of hypoxic human pulmonary arterial smooth muscle cells. Zhonghua jie he he hu xi za zhi = Chin J Tuberc Respir Dis 29(11):727–730

Irani F, Kalkstein S, Moberg EA et al (2011) Neuropsychological performance in older patients with schizophrenia: a meta-analysis of cross-sectional and longitudinal studies. Schizophr Bull 37(6):1318–1326PubMedCrossRef

Keefe RS, Harvey PD, Goldberg TE et al (2008) Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr Res 102(1–3):108–115PubMedCrossRef

Keefe RS, Fox KH, Harvey PD et al (2011) Characteristics of the MATRICS consensus cognitive battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res 125(2–3):161–168PubMedCrossRef

Kern RS, Gold JM, Dickinson D et al (2011) The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res 126(1–3):124–131PubMedCrossRef

Kim JH, Lee J, Kim YB et al (2014) Association between subjective well-being and depressive symptoms in treatment-resistant schizophrenia before and after treatment with clozapine. Compr Psychiatry 55(3):708–713PubMedCrossRef

Kohen R, Nyska A (2002) Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol 30(6):620–650PubMedCrossRef

Kolosova NG, Shcheglova TV, Sergeeva SV et al (2006) Long-term antioxidant supplementation attenuates oxidative stress markers and cognitive deficits in senescent-accelerated OXYS rats. Neurobiol Aging 27(9):1289–1297PubMedCrossRef

Li HC (2006) Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study. J Zhejiang Univ Sci B 7(12):981–986PubMedPubMedCentralCrossRef

Li XF, Zheng YL, Xiu MH et al (2011) Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35(4):1064–1067PubMedCrossRef

Lohr JB, Kuczenski R, Niculescu AB (2003) Oxidative mechanisms and tardive dyskinesia. CNS Drugs 17(1):47–62PubMedCrossRef

Mace J, Porter R, O’Brien J et al (2008) Cognitive effects of acute tryptophan depletion in the healthy elderly. Acta Neuropsychiatrica 20(2):78–86PubMedCrossRef

Martinez-Cengotitabengoa M, Mac-Dowell KS, Leza JC et al (2012) Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res 137(1–3):66–72PubMedCrossRef

Massaad CA, Klann E (2011) Reactive oxygen species in the regulation of synaptic plasticity and memory. Antioxid Redox Signal 14(10):2013–2054PubMedPubMedCentralCrossRef

McCleery A, Ventura J, Kern RS et al (2014) Cognitive functioning in first-episode schizophrenia: MATRICS consensus cognitive battery (MCCB) profile of impairment. Schizophr Res 157(1–3):33–39PubMedPubMedCentralCrossRef

Mendoza-Nuñez VCM, Retana-Ugalde R, Sánchez-RodríGuez MA et al (1999) DNA damage in lymphocytes of elderly patients in relation with total antioxidant levels. Mech Ageing Dev 108(1):9–23PubMedCrossRef

Mendoza-Núñez VCM, Retana-Ugalde R, Vargas-Guadarrama LA et al (2001) Total antioxidant levels, gender, and age as risk factors for DNA damage in lymphocytes of the elderly. Mech Ageing Dev 122(8):835–847PubMedCrossRef

Miljevic CD, Nikolic-Kokic A, Blagojevic D et al (2018) Association between neurological soft signs and antioxidant enzyme activity in schizophrenic patients. Psychiatry Res 269:746–752PubMedCrossRef

Miller NJ, Rice-Evans C, Davies MJ et al (1993) A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 84(4):407–412PubMedCrossRef

Mintz J, Kopelowicz A (2007) CUtLASS confirms CATIE. Arch Gen Psychiatry 64(8):978PubMedCrossRef

Nicolle MM, Gonzalez J, Sugaya K et al (2001) Signatures of hippocampal oxidative stress in aged spatial learning-impaired rodents. Neuroscience 107(3):415–431PubMedCrossRef

Nieuwenstein MR, Aleman A, Haan EHFD (2001) Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. J Psychiatr Res 35(2):119–125PubMedCrossRef

Ozcan ME, Gulec ME, Polat R et al (2004) Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 19(2):89–95PubMedCrossRef

Padurariu M, Ciobica A, Dobrin I et al (2010) Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 479(3):317–320PubMedCrossRef

Palmer BW, Dawes SE, Heaton RK (2009) What do we know about neuropsychological aspects of schizophrenia? Neuropsychol Rev 19(3):365–384PubMedPubMedCentralCrossRef

Poo MM (2001) Neurotrophins as synaptic modulators. Nat Rev Neurosci 2(1):24–32PubMedCrossRef

Radak Z, Kumagai S, Taylor AW et al (2007) Effects of exercise on brain function: role of free radicals. Appl Physiol Nutr Metab 32(5):942–946PubMedCrossRef

Raffa M, Atig F, Mhalla A et al (2011) Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry 11:124PubMedPubMedCentralCrossRef

Rajji TK, Mulsant BH (2008) Nature and course of cognitive function in late-life schizophrenia: a systematic review. Schizophr Res 102(1–3):122–140PubMedCrossRef

Rajji TK, Voineskos AN, Butters MA et al (2013) Cognitive performance of individuals with schizophrenia across seven decades: a study using the MATRICS consensus cognitive battery. Am J Geriatr Psychiatry 21(2):108–118PubMedPubMedCentralCrossRef

Rajji TK, Miranda D, Mulsant BH (2014) Cognition, function, and disability in patients with schizophrenia: a review of longitudinal studies. Can J Psychiatry 59(1):13–17PubMedPubMedCentralCrossRef

Ramos-Chavez LA, Roldan-Roldan G (2018) Low serum tryptophan levels as an indicator of global cognitive performance in nondemented women over 50 years of age. Oxid Med Cell Longev 2018:8604718PubMedPubMedCentral

Reddy R (2003) Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 62(3):205–212PubMedCrossRef

Ruiz-Litago F, Seco J, Echevarria E et al (2012) Adaptive response in the antioxidant defence system in the course and outcome in first-episode schizophrenia patients: a 12-months follow-up study. Psychiatry Res 200(2–3):218–222PubMedCrossRef

Stuss DT, Floden D, Alexander MP et al (2001) Stroop performance in focal lesion patients: dissociation of processes and frontal lobe lesion location. Neuropsychologia 39(8):771–786PubMedCrossRef

Tan SP, Jie-Feng C, Fan FM et al (2014) Smoking, MATRICS consensus cognitive battery and P50 sensory gating in a Han Chinese population. Drug Alcohol Depend 143:51–57PubMedCrossRef

Valko M, Leibfritz D, Moncol J et al (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39(1):44–84PubMedCrossRef

Virit O, Altindag A, Yumru M et al (2009) A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology 60(2):87–93PubMedCrossRef

Wang N, Wei J, Liu Y et al (2016) Discovery of biomarkers for oxidative stress based on cellular metabolomics. Biomarkers 21(5):449–457PubMedCrossRef

Wu Z, Zhang XY, Wang H et al (2012) Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: inverse association with positive symptoms. Prog Neuropsychopharmacol Biol Psychiatry 36(1):34–38PubMedCrossRef

Wu JQ, da Chen C, Tan YL et al (2014) Cognition impairment in schizophrenia patients with tardive dyskinesia: association with plasma superoxide dismutase activity. Schizophr Res 152(1):210–216PubMedCrossRef

Yao JK, Keshavan MS (2011) Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 15(1):2011–2035PubMedPubMedCentralCrossRef

Yao JK, Reddy R (2011) Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. Antioxid Redox Signal 15(7):1999–2002PubMedPubMedCentralCrossRef

Yao JK, Reddy R, Van Kammen DP (1998) Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 80(1):29–39PubMedCrossRef

Zhang XY, Chen DC, Xiu MH et al (2012a) Plasma total antioxidant status and cognitive impairments in schizophrenia. Schizophr Res 139(1–3):66–72PubMedCrossRef

Zhang XY, Liu L, Liu S et al (2012b) Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Am J Psychiatry 169(9):974–981PubMedCrossRef

Zhang XY, Chen DC, Xiu MH et al (2013a) Clinical symptoms and cognitive impairment associated with male schizophrenia relate to plasma manganese superoxide dismutase activity: a case-control study. J Psychiatr Res 47(8):1049–1053PubMedCrossRef

Zhang XY, Chen DC, Xiu MH et al (2013b) Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls. Schizophr Res 143(2–3):301–306PubMedCrossRef

Zhang Y, Chen X, Yang L et al (2015) Effects of rosmarinic acid on liver and kidney antioxidant enzymes, lipid peroxidation and tissue ultrastructure in aging mice. Food Funct 6(3):927–931PubMedCrossRef

Zou YZ, Cui JF, Wang J et al (2009) Clinical reliability and validity of the chinese version of measurement and treatment research to improve cognitive in schizophrenia consensus cognitive battery. Chin J Psychiatry 42(1):29–33

Title: Plasma total antioxidant status and cognitive impairments in first-episode drug-naïve patients with schizophrenia
Authors: Ting Xie
Qiongwei Li
Xingguang Luo
Li Tian
Zhiren Wang
Shuping Tan
Song Chen
Guigang Yang
Huimei An
Fude Yang
Yunlong Tan
Publication date: 09-04-2019
Publisher: Springer Netherlands
Published in: Cognitive Neurodynamics / Issue 4/2019
Print ISSN: 1871-4080
Electronic ISSN: 1871-4099
DOI: https://doi.org/10.1007/s11571-019-09530-3

Springer Professional

Abstract

Please log in to get access to your license.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Technik"

Springer Professional "Wirtschaft"

Other articles of this Issue 4/2019

Bifurcation analysis and diverse firing activities of a modified excitable neuron model

U1 snRNA over-expression affects neural oscillations and short-term memory deficits in mice

Theoretical models of reaction times arising from simple-choice tasks

Complex temporal patterns processing by a neural mass model of a cortical column

Flanker paradigm contains conflict and distraction factors with distinct neural mechanisms: an ERP analysis in a 2-1 mapping task

Consensus of uncertain multi-agent systems with input delay and disturbances